Aclarion, Inc. (NASDAQ:ACON): Advancing AI in Chronic Back Pain Solutions

Font: Financial Modeling Prep  • May 11, 2026

• Aclarion, Inc. (NASDAQ:ACON) demonstrates robust operational growth with a 196% increase in Nociscan platform scan volume, indicating strong market adoption for its AI-powered chronic back pain solution.
• Insider confidence is highlighted by CEO Ness Brent's share purchase, alongside advancements in clinical research with the CLARITY Trial.
• The company maintains a strong financial position with no debt, sufficient cash reserves, and a $2.50 million share repurchase program.

Aclarion, Inc. is a healthcare technology company that uses artificial intelligence (AI) to help doctors identify the source of chronic low back pain. Its main product is the Nociscan platform. The company has a market capitalization of approximately $1.65 million, with its stock recently trading at $3.10 per share.

On May 11, 2026, an insider transaction showed confidence in the company's direction. Ness Brent, a Director and the Chief Executive Officer of ACON, purchased 6,289 shares of common stock at a price of $3.18 each. This transaction increased his total ownership in the company to 6,300 shares.

This move comes as ACON reports strong operational growth. The company announced a 196% annual increase in scan volume for its Nociscan platform in the first quarter of 2026, as highlighted by GlobeNewswire. This suggests that more clinics are adopting its technology to help patients with chronic back pain.

The company is also advancing its clinical research. ACON is accelerating enrollment for its CLARITY Trial by adding its first private practice site in Los Angeles, as highlighted by PrismMediaWire. To support commercial growth, the company also granted its new Commercial Director an inducement stock option to purchase 17,000 shares.

Aclarion maintains a strong financial position with no debt and enough cash to fund operations into the second half of 2027. The company also announced a $2.50 million share repurchase program. This program allows the company to buy back its own shares from the market, which can increase the value of the remaining shares.